The Claim
Recombinant human TSH induces a strong cyclic AMP response in differentiated orbital fibroblasts from patients with Graves' ophthalmopathy but does not stimulate significant hyaluronan synthesis in the majority of tested cultures.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In cells taken from patients with Graves' ophthalmopathy, recombinant human TSH triggers a strong increase in cyclic AMP but does not cause a significant increase in hyaluronan production in most cultures.
See the scientific wording
Recombinant human TSH induces a strong cyclic AMP response in differentiated orbital fibroblasts from patients with Graves' ophthalmopathy but fails to stimulate significant hyaluronan synthesis in all but one of the tested cultures.
When the thyroid-stimulating hormone binds to its receptor on eye tissue cells, it strongly activates a chemical signal called cAMP, but this signal does not turn on the production of the swelling-causing goo called hyaluronan. A different trigger, not the hormone itself, is needed to make that goo.
What the research says
1 studyIn eye cells from people with Graves' eye disease, the study found that a lab-made version of the thyroid hormone trigger (TSH) makes a chemical called cAMP spike, but it almost never makes the gooey substance (hyaluronan) that causes swelling. So yes, the trigger works for one thing but not the other.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.